Efficacy and safety of botulinum toxin type A (Botox®) in blepharospasm and hemifacial spasm Blefarospazm ve hemifasiyal spazmda botilinum toksin tip A (Botox®)'ni{dotless}n etkinlik ve güvenirliǧi


ÇABALAR M., Yayla V., Çulha A., Selçuk Ö.

Turkiye Klinikleri Journal of Medical Sciences, cilt.33, sa.5, ss.1231-1235, 2013 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 5
  • Basım Tarihi: 2013
  • Doi Numarası: 10.5336/medsci.2012-32060
  • Dergi Adı: Turkiye Klinikleri Journal of Medical Sciences
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.1231-1235
  • Anahtar Kelimeler: Blepharospasm, Botulinum toxins, Hemifacial spasm, Type A
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: Botox®, a preparation of botulinum toxin type A, is most widely used for blepharospasm (BPS) and hemifacial spasm (HFS). In this study, we present 82 patients who have been treated with Botox®. Material and Methods: This retrospective study included 15 BPS and 67 HFS patients who admitted to our clinic between May 2007 and December 2011. Botox® was diluted by sterile saline to adjust the dose to 5U/0.1 ml before injection. Pretarsal administration was applied. The average dose of Botox® required for an optimal response was 30-35 MU for BPS, 25-30 MU for HFS. Results: The therapeutic effect started after 3 to 5 days, and initial repetitive efficacy intervals (REI) [2nd REI, BPS (13,9 months) and HFS (5,8 months)] were longer than the last mean REI [7th REI, BPS (5.9 months) and HFS (3.7 months)], and there were statistically significant differences between BPS and HFS groups (p<0.05). The treatment was effective in both BPS and HFS. Adverse effects occurred in 7.29% of the injection series. Conclusion: BTX-A is established as an effective and safe agent in the treatment of BPS and HFS. The side effects of BTA-X administration may be reduced with the help of injection material used and the application technique. © 2013 by Türkiye Klinikleri.